TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33984675
Drug: Concomitant systemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant systemic therapy
Study: 33984675
Drug: Treatment line
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment line ≥3
Study: 33985811
Drug: Neoadjuvant pembrolizumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant pembrolizumab (200 mg for 2 cycles before surgery)
Study: 33986031
Drug: Anticoagulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation therapy (initial therapy)
Study: 33986057
Drug: Allogeneic umbilical
Normalized name: Allogeneic umbilical cord mesenchymal stem cells
DrugBank: Allogeneic umbilical cord mesenchymal stem cells (DB18367)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic umbilical cord-derived mesenchymal stem/stromal cells (UC-MSCs), two doses with an intervention interval of 3 months.
Study: 33986057
Drug: Standard COPD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard COPD medication treatment based on GOLD 2019 guidelines and Vietnam Ministry of Health protocol.
Study: 33988517
Drug: Digital Cognitive
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital Cognitive Behavioral Therapy (CBT)
Study: 33988881
Drug: Surgery post-Vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Surgery post-Vismodegib treatment
Study: 33989558
Drug: Loncastuximab tesirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loncastuximab tesirine (150 μg/kg for two cycles, then 75 μg/kg thereafter, intravenously on day 1 of each 21-day cycle)
Study: 33989764
Drug: BITC in
Normalized name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 4 g in 100 g / AVOBENZONE 3 g in 100 g / OCTISALATE 5 g in 100 g TOPICAL STICK [Bitchstix Grapefruit SPF 30 Sunscreen Lip Balm SPF 30]
Approvals — FDA: no, EMA: no, PMDA: no
Description: BITC in combination with other drugs
Study: 33990076
Drug: e-CBT program
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: e-CBT program delivered through the Online Psychotherapy Tool, 12 weekly sessions tailored to MDD.
Study: 33990076
Drug: In-person CBT,
Approvals — FDA: no, EMA: no, PMDA: no
Description: In-person CBT, 12 weekly sessions.
Study: 33990101
Drug: Stopping disease-modifying
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stopping disease-modifying therapies (DMTs)
Study: 33990507
Drug: Endothelin receptor
Normalized name: Endothelin receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin receptor antagonists (ERA), specifically atrasentan, in addition to blockade of the renin-angiotensin-aldosterone system
Study: 35070795
Drug: Endothelin receptor
Normalized name: Endothelin receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endothelin receptor antagonists (ERA)
Study: 33990663
Drug: 23 mg
Normalized name: morphine 0.23 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 23 mg donepezil sustained release
Study: 33990663
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg donepezil immediate release
Study: 33991326
Drug: Apomorphine Sublingual
Normalized name: apomorphine Sublingual Film
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apomorphine Sublingual Film (APL) at doses of 15/20/25/30 mg
Study: 33991326
Drug: Subcutaneous Apomorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Apomorphine (SC-APO) at doses of 2/3/4/5 mg
Study: 33991326
Drug: Subcutaneous Apomorphine-GO
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous Apomorphine-GO (SC-APO-GO) at doses of 2/3/4/5 mg
Study: 37029871
Drug: Bisoprolol/Perindopril single-pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol/Perindopril single-pill combination (SPC)
Study: 33991512
Drug: Enfortumab vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enfortumab vedotin (1.25 mg/kg IV on days 1, 8, and 15 of every 28-day cycle)
Study: 33992564
Drug: N-terminal pro-B-type
Normalized name: N-terminal pro-B-type natriuretic peptide
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-terminal pro-B-type natriuretic peptide-guided titration of guideline-directed medical therapy (GDMT)
Study: 33993135
Drug: Psychedelic-assisted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychedelic-assisted therapy
Study: 33993383
Drug: Alisertib (MLN8237)
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib (MLN8237) 100 mg/m² combined with weekly irinotecan (20 mg twice per day on days 1-3 and 8-10)
Study: 33993383
Drug: Alisertib (MLN8237)
Normalized name: Alisertib
DrugBank: Alisertib (DB05220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alisertib (MLN8237) combined with weekly irinotecan
Study: 33993741
Drug: Regorafenib with
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib with trifluridine/tipiracil (TAS-102) combination treatment
Study: 33993741
Drug: Trifluridine/tipiracil at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil at 25 mg/m2
Study: 33994151
Drug: Accelerated Partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated Partial Breast Irradiation (APBI) using a single fraction of Multi-Catheter Interstitial High-Dose Rate Brachytherapy (MIB)
Study: 33995015
Drug: Cannabidiol (CBD)
Normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cannabidiol (CBD) up to 800 mg/day for 4 weeks
Study: 33995015
Drug: Amisulpride (AMI)
DrugBank: Amisulpride (DB06288)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amisulpride (AMI) up to 800 mg/day for 4 weeks
Study: 33995239
Drug: Epigallocatechin Gallate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epigallocatechin Gallate, dosage and duration not available
Study: 33995588
Drug: Matched targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched targeted therapy based on ctDNA analysis and/or tumor molecular profiling
Study: 33996579
Drug: Early Oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early Oral Feeding (EOF)
Study: 33996589
Drug: Pyrotinib plus
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib plus vinorelbine (oral and intravenous)
Study: 33997459
Drug: Defined menu
Normalized name: refined almond oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Defined menu plans with a cardioprotective diet and additional 3 g of long-chain n-3 PUFA from fish oil
Study: 33997740
Drug: Neoadjuvant vismodegib
Normalized name: Vismodegib
DrugBank: Vismodegib (DB08828)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Neoadjuvant vismodegib 150 mg administered orally once daily for 4 to 10 months before planned surgery
Study: 33998278
Drug: Control (Angiotensin-Receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Angiotensin-Receptor Blockers)
Study: 33998660
Drug: Lacosamide (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacosamide (200 mg to 600 mg per day)
Study: 33998664
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of daily calf and hamstring stretching for six weeks
Study: 33998664
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of daily calf, quadriceps, and hamstring stretching
Study: 33998674
Drug: Angiotensin-converting enzyme
Normalized name: ACE - Angiotensin-converting enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Angiotensin-converting enzyme (ACE) inhibitors (captopril or enalapril)
Study: 33998674
Drug: Alpha blockers
Normalized name: ALPHA BLOCKERS/RELATED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha blockers (buflomedil or moxisylyte)
Study: 33998674
Drug: Thromboxane synthase
Normalized name: Thromboxane synthase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thromboxane synthase inhibitors (dazoxiben)
Study: 33998674
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (ketanserin)
Study: 33998674
Drug: Phosphodiesterase inhibitors
Normalized name: Phosphodiesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase inhibitors (vardenafil, cilostazol or PF-00489791)
Study: 33999158
Drug: Onasemnogene abeparvovec
Normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Onasemnogene abeparvovec (therapeutic dose, 1.1×10^14 vg/kg)
Study: 33999158
Drug: Onasemnogene abeparvovec
Normalized name: onasemnogene abeparvovec
DrugBank: Onasemnogene abeparvovec (DB15528)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Onasemnogene abeparvovec (low dose, 6.7×10^13 vg/kg)
Study: 33999564
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy (PT) for range of motion, strengthening, and return to function recommended by 96% (27/28) of surgeons, starting at a mean of 2.6 weeks postoperatively (range: 0 to 16 weeks).
Study: 34000061
Drug: Standard ED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ED treatment
Study: 34000246
Drug: Cemiplimab 350
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 350 mg intravenously every 3 weeks for up to 93 weeks
Study: 34000620
Drug: 3 μg/kg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 μg/kg/day sargramostim
Study: 34000747
Drug: Stand-alone Xen45
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stand-alone Xen45 gel stent without mitomycin C (MMC)
Study: 34000747
Drug: Stand-alone Xen45
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stand-alone Xen45 gel stent with mitomycin C (MMC)
Study: 34000747
Drug: Xen45 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xen45 gel stent combined with cataract surgery without mitomycin C (MMC)
Study: 34000747
Drug: Xen45 gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xen45 gel stent combined with cataract surgery with mitomycin C (MMC)
Study: 34000994
Drug: Freeze-dried highbush
Normalized name: BLACKBERRY MESOCARP FREEZE DRIED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Freeze-dried highbush blueberry powder (BBP), 50 g daily for 8 weeks
Study: 34001010
Drug: Avelumab, administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab, administered in 4 doses as a short course of immunotherapy.
Study: 34001113
Drug: Self-admission to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-admission to psychiatric inpatient treatment
Study: 34001145
Drug: Non-invasive screening
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive screening for HCV antibodies (Ab) by finger prick and facilitated referral to a specialist.
Study: 34001647
Drug: Canakinumab therapy
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab therapy
Study: 34001692
Drug: Anti-IL-17A therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anti-IL-17A therapy
Study: 34002356
Drug: Daridorexant 25
Normalized name: daridorexant 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daridorexant 25 mg orally
Study: 34003074
Drug: Cisplatin, 5FU,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin, 5FU, and afatinib every 21 days followed by afatinib maintenance monotherapy
Study: 34004576
Drug: Small molecules
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Small molecules proposed to reverse the gene expression signature of OS based on a meta-analysis of gene expression.
Study: 34006027
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment programme for eating disorders including hospitalisation, day hospital, and outpatient settings.
Study: 34006291
Drug: Matched therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched therapy based on actionable genetic alterations (AGAs)
Study: 34006499
Drug: Cabozantinib 40
Normalized name: cabozantinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 40 mg daily, orally, in combination with durvalumab 1500 mg, intravenously, every 28 days.
Study: 34007150
Drug: Intravitreal Aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Aflibercept injection (IAI), 5 monthly injections followed by ProReNata regimen
Study: 34007150
Drug: Intravitreal Aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal Aflibercept injection (IAI)
Study: 34007899
Drug: Nicotine patches
Normalized name: NICOTINE 7 mg in 1 g TRANSDERMAL PATCH [Sielkin QUIT SMOKING NICOTINE PATCHES]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patches (5-week supply mailed free-of-charge)
Study: 34008342
Drug: Escitalopram for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram for 8 weeks followed by escitalopram monotherapy for responders or adjunctive aripiprazole for non-responders for an additional 8 weeks.
Study: 34008342
Drug: Adjunctive aripiprazole
Normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive aripiprazole for non-responders after initial treatment with escitalopram.
Study: 34009391
Drug: Complementary and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary and Integrative Health (CIH) therapies including chiropractic, acupuncture, multimodal individualized interventions/programs, physiotherapy, and anthroposophic medicine therapy
Study: 34009501
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg every 2 weeks until disease progression, unacceptable toxicity, or withdrawal.
Study: 34009501
Drug: Bintrafusp alfa
Normalized name: Bintrafusp alfa
DrugBank: Bintrafusp alfa (DB15387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bintrafusp alfa 1200 mg every 2 weeks.
Study: 34011995
Drug: HER2 blockade
Normalized name: RHUMAB HER2
DrugBank: Trastuzumab (DB00072)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: HER2 blockade treatment, specific dosage and duration not mentioned
Study: 34012418
Drug: Intensive training
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive training for upper extremity function, details on dosage and duration not available
Study: 34012920
Drug: Apatinib (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apatinib (500 mg per day for a cycle of 28 days)
Study: 34013139
Drug: Endoluminal negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoluminal negative pressure (ENP) therapy via polyurethane foam (EsoSponge)
Study: 34014326
Drug: Self-administered screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administered screening approach
Study: 34014326
Drug: Staff-administered screening
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staff-administered screening approach
Study: 34015791
Drug: Ultrabrief Pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrabrief Pulse Right Unilateral Electroconvulsive Therapy (UB-RUL ECT)
Study: 34016561
Drug: Ibudilast (MN-166),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibudilast (MN-166), dosage and duration not specified
Study: 34016873
Drug: High pancreatic
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High pancreatic enzyme replacement therapy (PERT) dosing (>2000 lipase units/kg per meal)
Study: 34016873
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of acid suppressive medications
Study: 34016873
Drug: High levels
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High levels of fecal calprotectin (fCP) (>200 μg/g)
Study: 34017073
Drug: 10 mg ruxolitinib
Normalized name: ruxolitinib 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg ruxolitinib b.i.d. for the first 12 weeks, then up-titrations of up to 25 mg b.i.d. based on efficacy and platelet counts
Study: 34018141
Drug: CRP results
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP results ≥ 15.3 mg/dL on day 3
Study: 34018141
Drug: CRP results
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRP results ≥ 9.1 mg/dL on day 5
Study: 34019108
Drug: Rifampin 600
Normalized name: rifampin 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampin 600 mg daily from Days 9-18
Study: 34019108
Drug: Efavirenz 600
Normalized name: efavirenz 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Efavirenz 600 mg daily from Days 9-18
Study: 34019108
Drug: Fedratinib 500
Normalized name: FEDRATINIB
DrugBank: Fedratinib (DB12500)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fedratinib 500 mg on Day 1 and Day 17
Study: 34019698
Drug: Trastuzumab in
Normalized name: trastuzumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab in combination with FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) as perioperative treatment.
Study: 34019698
Drug: FLOT (5-fluorouracil,
Approvals — FDA: no, EMA: no, PMDA: no
Description: FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel) alone as perioperative treatment.
Study: 34022698
Drug: Immune-checkpoint inhibitors
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immune-checkpoint inhibitors (ICI)
Study: 34022820
Drug: Quarterly HIV
Normalized name: Quarter Mate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quarterly HIV prevention services including clinical examination, HIV testing, screening and treatment for other sexually transmitted infections, peer-led counselling and support, provision of condoms and lubricants.
Study: 34025640
Drug: Intracranial and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracranial and systemic immunoadjuvants with low-dose reirradiation
Study: 34025681
Drug: Low-dose lenalidomide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lenalidomide plus dexamethasone
Study: 34026784
Drug: Anti-BCMA CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-BCMA CAR-T cell therapy followed by haploidentical hematopoietic stem cell transplantation (haploidentical-HSCT)
Study: 34026784
Drug: Anti-BCMA CAR-T
Normalized name: Anti-BCMA CAR T cell
DrugBank: Idecabtagene vicleucel (DB16665)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-BCMA CAR-T cell therapy
Study: 34027223
Drug: Health system
Normalized name: Leva Pelvic Health System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health system intervention combined with an aspirin awareness media campaign
Study: 34027291
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg daily)
Study: 34028393
Drug: Novel 5-strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel 5-strain probiotic blend (Bl-04, Bi-07, HN019, NCFM, Lpc-37) administered once daily for 30 days
Study: 34029345
Drug: COVID-19 vaccine
Normalized name: COVID-19 VACCINE
DrugBank: VidPrevtyn Beta (DB16427)
Approvals — FDA: no, EMA: no, PMDA: no
Description: COVID-19 vaccine assessment through the HeartlineTM mobile application
Study: 34029490
Drug: Plasma cortisol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma cortisol level after a 1-mg dexamethasone suppression test
Study: 34029566
Drug: ACE inhibitors
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitors (ACEis) and angiotensin-receptor blockers (ARBs)
Study: 34029994
Drug: PEG-interferon-α-based therapies
Normalized name: PEG-Interferon alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PEG-interferon-α-based therapies
Study: 34030162
Drug: Therapeutic approaches
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic approaches to modulate intestinal microbiota (dietary interventions, probiotic administration, fecal microbiota transplantation)
Study: 34030162
Drug: Microbiota modulators
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microbiota modulators
Study: 37277275
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg BID
Study: 34030986
Drug: Oral azithromycin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral azithromycin, ethambutol, and rifampin (simultaneous doses in fasting state and with food and pancreatic enzymes)
Study: 34030986
Drug: Fasting doses
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fasting doses of azithromycin, ethambutol, and rifampin
Study: 34031051
Drug: Intravenous isavuconazonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous isavuconazonium sulfate (10 mg/kg body weight, maximum 372 mg)
Study: 34031051
Drug: Oral isavuconazonium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral isavuconazonium sulfate (10 mg/kg body weight, maximum 372 mg)
Study: 34031756
Drug: LY01610 (liposome-encapsulated
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY01610 (liposome-encapsulated irinotecan) administered intravenously every 2 weeks, with the first cycle in dose escalation being 3 weeks.
Study: 34033120
Drug: Bifonazole cream
Normalized name: bifonazole
DrugBank: Bifonazole (DB04794)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifonazole cream
Study: 34033178
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups received standard behavioral support and nicotine replacement therapy
Study: 34034795
Drug: CD38-targeted chimeric
Normalized name: Anti-CD38-targeted IGG4-attenuated IFNA TAK-573
DrugBank: Modakafusp alfa (DB16399)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD38-targeted chimeric antigen receptor T (CAR-T-38) cells
Study: 34035077
Drug: Intensive glucose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose control and blood pressure-lowering therapy
Study: 34035077
Drug: Intensive glucose-lowering
Normalized name: biguanide blood glucose lower drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive glucose-lowering and BP-lowering treatments